dokumendiregister.ee
Sissetulev kiriAvalik

Farmakopöa töökava asjus

Ravimiamet · 27. jaanuar 2025
Viit
REP-1/396-1
Registreeritud
27. jaanuar 2025
Dokumendi liik
Sissetulev kiri
Adressaat
European Directorate for the Quality of Medicines & HealthCare
Saabumis/saatmisviis
e-post
Funktsioon
REP Euroopa Farmakopöaga seotud asjaajamine
Sari
REP-1 Euroopa Farmakopöa alane kirjavahetus
Toimik
REP-1/2025
Vastutaja
Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)

Failid

Sisu (failidest)

Signe Leito Saatja: [email protected] Saatmisaeg: neljapäev, 23. jaanuar 2025 10:25 Adressaat: Signe Leito Teema: Survey: Proposed addition to the work programme P4: Pitolisant hydrochloride and Pitolisant hydrochloride tablets: EDQM-2025-00340- mail Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Please make sure to include in any reply our mail reference: EDQM-2025-00340-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed addition of Pitolisant hydrochloride and Pitolisant hydrochloride tablets to the work programme P4. In order to have access to the survey, please copy and paste this link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=437182&newtest=Y&lang=en Deadline for replies: 25 February 2025. Thank you. With kind regards On behalf of Monica Sorinas Jimeno ___ Villy Nikolova Administrative Support Assistant European Pharmacopoeia Department EDQM Council of Europe 1 Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://www.edqm.eu/store Stay connected with the EDQM Confidentiality Notice: This e-mail and any attached files may contain confidential information that is intended only for the addressee(s). If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail (including any attached files) is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by using the reply function and then permanently delete this e-mail (including any attached files). Thank you. **************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2025-00340-mail 2
Allikas: Ravimiamet dokumendiregister →